Welcome to our dedicated page for Semler Scientific SEC filings (Ticker: SMLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Semler Scientific, Inc. (Nasdaq: SMLR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. These documents cover both its healthcare operations and its Bitcoin treasury activities, offering investors insight into how the company reports revenues and expenses from its medical device and software business alongside unrealized gains and losses from changes in the fair value of its Bitcoin holdings.
In its periodic reports, Semler Scientific presents financial statements that reflect income from operations in its healthcare segment, operating expenses such as engineering and product development, sales and marketing, and general and administrative costs, as well as line items related to digital assets. The filings detail the fair value of Bitcoin classified as intangible digital assets, changes in that fair value, and the impact on pre-tax income. They also describe capital-raising transactions, including at-the-market equity offering programs and 4.25% convertible senior notes due 2030, and provide information on stockholders’ equity.
Current reports on Form 8-K document material events such as the adoption and evolution of Semler Scientific’s Bitcoin treasury strategy, the master loan agreement with Coinbase Credit Inc. secured by Bitcoin collateral, and the agreement in principle to settle a civil investigative demand from the U.S. Department of Justice. Other 8-K filings describe a strategic plan to realign operations through headcount reductions and expense curtailment, a non-executive retention program, executive officer changes and the Agreement and Plan of Merger providing for the acquisition of Semler Scientific by Strive, Inc. in an all-stock transaction.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify items such as segment performance, digital asset disclosures, capital structure changes and merger-related information. Investors can also use the filings to monitor topics like BTC Yield as a disclosed key performance indicator, the structure of Bitcoin-related financing arrangements and other regulatory disclosures relevant to SMLR.
Strive, Inc. filed a Rule 425 communication about its proposed business combination with Semler Scientific, Inc. (SMLR). Strive has filed a Registration Statement on Form S-4 to register Class A common stock to be issued in connection with the transaction. A combined information statement/proxy statement/prospectus will be sent to Semler Scientific stockholders to seek their approval.
The communication includes forward-looking statement cautions and directs investors to the SEC’s website and company investor pages for the Registration Statement and related materials when available.
Strive, Inc. released a Rule 425 communication about its proposed business combination with Semler Scientific (SMLR), which was reposted on X.com by board member Pierre Rochard on November 10, 2025.
Strive has filed a Form S-4 to register Class A common stock to be issued in connection with the transaction. The S-4 includes an information statement/proxy statement/prospectus, and a definitive version will be sent to Semler stockholders to seek their approval.
The notice includes forward‑looking statement cautions, directs investors to the SEC and company websites for documents, identifies potential proxy solicitation participants, and states it is not an offer or solicitation.
Strive, Inc. filed a Rule 425 communication related to its proposed business combination with Semler Scientific (SMLR). The notice includes a forward‑looking statements caution and outlines that Strive has filed a Form S‑4 to register Class A common stock to be issued in the transaction. The S‑4 will include an information statement for Strive, a proxy statement for Semler Scientific, and a prospectus for Strive.
Semler Scientific stockholders will receive a definitive Information Statement/Proxy Statement/Prospectus to consider and vote on the proposed transaction. Investors are urged to read these materials when available, as they will contain important details about the companies and the deal. The communication emphasizes it is not an offer or solicitation to sell securities. Documents will be available free of charge on the SEC’s website and the companies’ investor relations pages.
Semler Scientific (SMLR) and Strive, Inc. announced a transaction-related communication under Rule 425, tied to their proposed business combination. The notice emphasizes forward-looking statement cautions and outlines the path to closing.
Strive has filed a Form S-4 to register the Class A common stock to be issued in the deal, which will include an information statement/proxy statement/prospectus. A definitive version will be sent to Semler Scientific stockholders to seek their approval. Investors are directed to review the S-4 and related materials when available on the SEC’s website and each company’s investor relations pages. The communication also clarifies this is not an offer to sell or solicit the purchase of securities.
Strive, Inc. filed a Rule 425 communication regarding its proposed business combination with Semler Scientific, Inc. The notice emphasizes forward‑looking statement cautions and directs investors to official SEC materials.
Strive has filed a Form S-4 to register Class A common stock to be issued in the transaction. A combined information statement, proxy statement, and prospectus will be sent to Semler stockholders to seek approval. The companies note that this is not an offer or solicitation and urge investors to read the Registration Statement and related documents when available.
Strive, Inc. issued a Rule 425 communication about its proposed business combination with Semler Scientific, Inc. Strive has filed a Registration Statement on Form S-4 to register Class A common stock to be issued in connection with the transaction, which will include an information statement for Strive, a proxy statement for Semler Scientific, and a prospectus for Strive.
A definitive Information Statement/Proxy Statement/Prospectus will be sent to Semler Scientific stockholders to seek their approval. The communication includes forward‑looking statement cautions and states it is not an offer or solicitation. Related documents, when available, can be obtained free of charge from the SEC’s website and each company’s investor relations pages.
Semler Scientific and Strive announced a proposed business combination and related investor communications filed under Rule 425. Strive has filed a Form S-4 to register Class A common stock to be issued in the transaction, which will include an information statement for Strive, a proxy statement for Semler Scientific, and a prospectus for Strive. Semler Scientific stockholders will receive definitive proxy materials to vote on the deal.
The communication emphasizes forward-looking statement cautions and directs investors to SEC filings for details, including Strive’s S-4 filings dated August 6, 2025 and October 10, 2025, and each company’s periodic reports. It clarifies this is not an offer to sell or buy securities; any offer will be made only by a prospectus meeting Section 10 of the Securities Act or an applicable exemption.
Strive, Inc. filed a Rule 425 communication regarding its proposed business combination with Semler Scientific, Inc. The message notes that Strive has filed a Form S-4 to register Class A common stock to be issued in the transaction and that an Information Statement/Proxy Statement/Prospectus will be sent to Semler stockholders to seek their approval.
The communication includes extensive forward-looking statement cautions and directs investors to the SEC’s website for free copies of the S-4 and related documents. It also states that directors, officers and employees of both companies may be participants in the proxy solicitation and concludes with a standard “no offer or solicitation” disclaimer.
Strive, Inc. issued a Rule 425 communication about its proposed business combination with Semler Scientific. Strive has filed a Form S-4 to register Class A common stock to be issued in the transaction, which will include an information statement, proxy statement and prospectus.
A definitive proxy will be sent to Semler Scientific stockholders to seek approval. The notice includes forward-looking statement cautions and clarifies it is not an offer or solicitation. Investors can access related SEC filings for full details.
Strive, Inc. filed a communication under Rule 425 regarding its proposed business combination with Semler Scientific, Inc. (SMLR). Strive has filed a Form S-4 to register Class A common stock to be issued in connection with the transaction, and a combined information statement/proxy statement/prospectus will be delivered to Semler Scientific stockholders to seek their approval.
The notice includes standard forward‑looking statement cautions and directs investors to the SEC’s website and company investor relations pages for the Registration Statement, proxy materials, and related filings. It also identifies that directors, officers, and employees of both companies may be participants in the proxy solicitation. The communication states it is not an offer to sell or solicit the purchase of securities.
FAQ
What is the current stock price of Semler Scientific (SMLR)?
What is the market cap of Semler Scientific (SMLR)?
